logo
Share SHARE
FONT-SIZE Plus   Neg

Celgene: Oral OTEZLA Shows Long-Term Benefits For Active Psoriatic Arthritis

Celgene International Sàrl, an unit of Celgene Corp. (CELG), reported results of additional analyses from the phase III trials of OTEZLA, the company's oral, selective inhibitor of phosphodiesterase 4 or PDE4. These included long-term (52-week) analyses from the PALACE 1, 2 and 3 trials of the impact of OTEZLA on psoriatic arthritis disease activity, safety and tolerability, in addition to a separate 16-week work productivity analysis from PALACE 1.

"People with psoriatic arthritis live with persistent symptoms of this painful disease," said Georg Schett, director of the Department of Internal Medicine III - Rheumatology and Immunology, University Hospital Erlangen, Germany. "These analyses of one-year data from the PALACE trials suggest that, based on the efficacy and safety data we've seen to-date, OTEZLA has the potential to help patients for the long-term management of manifestations of their psoriatic arthritis," he added.

The long-term (52-week) results from three trials showed that treatment with OTEZLA improved measures of psoriatic arthritis disease activity, including tender and swollen joints, compared with placebo at 16 weeks.

Long-term safety results from an analysis of pooled data from the PALACE 1, 2 and 3 trials identified no new safety findings for patients with psoriatic arthritis who were treated with OTEZLA for up to 52 weeks, compared with the previously reported 24-week safety results.

by RTT Staff Writer

For comments and feedback: editorial@rttnews.com

Business News

Quick Facts

Editors Pick
A search has been launched for a dog that was placed aboard a wrong WestJet flight and ended up in Hamilton. The labradoodle named Cooper was mistakenly put on a flight to Hamilton and got off its leash in the Ontario city after it was taken out of its kennel by airline staff for a walk. Network management services provider Real Matters Inc. has filed preliminary prospectus for initial public offering in Canada. The filing is done with Ontario Securities Commission. According to Bloomberg, the Canadian real estate data firm is planning to raise around C$125 million or $96 million. Struggling women's apparel retailer Bebe Stores Inc. will close all its stores by the end of May 2017. In a filing with the Securities and Exchange Commission on Friday, Brisbane, California-based Bebe said it expects to incur an impairment charge of about $20 million as a result of the store closures.
comments powered by Disqus
Follow RTT